Skip to main content
OpenTrials
Completed

NCT Number: NCT06989307

COVID-19 Serologies Among Healthcare Workers at CHSD (SERO2)

This study looks at how many healthcare workers at CHSD hospital developed antibodies against COVID-19 after the second and third waves of the pandemic and after receiving a vaccine. It aims to better understand who might still be at risk of infection, how long immunity lasts after getting COVID or the vaccine, and how reliable previous antibody tests were. Blood samples will be collected from volunteer hospital staff during a one-month period to measure their antibody levels and compare them to earlier results.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Volunteers from the hospital staff who have signed a new informed consent form

Exclusion criteria

  • Refusal to participate (no signed consent form)
  • Staff unavailable during the blood sampling period
  • Participation only in the first seroprevalence survey without consent for the second

Treatment and study plan

Primary outcomes

  1. SARS-CoV-2 antibody prevalence (seroprevalence) among healthcare workers at CHSD

    Time frame: 1 month (during the serological testing period)

Sponsors and collaborators

Lead sponsor

Centre Hospitalier de Saint-Denis

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
May 25, 2025
Registry last updated
May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.